Two groups have filed a lawsuit over an executive order by West Virginia's governor granting religious exemptions from ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 ...

An FDA committee on Thursday recommended that COVID-19 vaccines for the 2025-2026 respiratory virus season — which, for the ...

The NB.1.8.1 COVID-19 variant, dominant in China, is spreading in the U.S. via international travelers, with cases detected ...

World Health Organization (WHO) member countries adopted a new treaty on May 20, 2025, to improve international coordination ...

The FDA picked the LP.8.1 Covid strain for the fall vaccines, fueling concerns that the shots may be limited to only the most ...

In a major and controversial policy shift, the FDA announced in a New England Journal of Medicine article that updated ...

Low uptake may reflect barriers—misinformation, access or shifting insurance coverage—not simply waning need.

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...

Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were instrumental in saving lives during the COVID pandemic.

The much-anticipated report calls for increased scrutiny of the vaccine schedule and describes the nation’s children as overmedicated.

On May 22, an FDA advisory committee unanimously recommended COVID-19 vaccine manufacturers target the JN.1 variant in their formulations.  The Vaccines and Related Biological Products Advisory ...